US FDA Defends Review Consistency In Second CRL For Replimune’s RP1

 
• By Bridget Silverman
  
rejected FDA complete response letter
Replimune's resubmitted BLA earned a second complete response letter. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Complete Response Letters

More from Cell & Gene Therapies